SCHEMBL427900

SCHEMBL427900

CCN(CC)CCCNCCCCNCCCN

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.59
ALOX15 P16050 3/20 0.56
CA12 O43570 3/20 0.56
CA2 P00918 3/20 0.56
CA4 P22748 3/20 0.56
CA6 P23280 3/20 0.56
CA5A P35218 3/20 0.56
CA7 P43166 3/20 0.56
CA9 Q16790 3/20 0.56
CA14 Q9ULX7 3/20 0.56
CA5B Q9Y2D0 3/20 0.56
F13A1 P00488 2/20 0.56
CYP1A2 P05177 2/20 0.56
THPO P40225 2/20 0.56
CASP2 P42575 2/20 0.56
CYP2C19 P33261 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
RECQL P46063 1/20 0.56
HSD17B10 Q99714 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28341342 0.98 UBE2N (0.58) TDP1ALOX15CA12CA2CA4
Hydrochloric Acid SCHEMBL6114403 0.98 UBE2N (0.58) TDP1ALOX15CA12CA2CA4
SCHEMBL323710 0.98 TDP1 (0.61) TDP1ALOX15CA12CA2CA4
SCHEMBL7522951 0.96 ALOX15 (0.56) TDP1ALOX15CA12CA2CA4
SCHEMBL4562189 0.96 PAOX (0.55) TDP1ALOX15CA12CA2CA4
SCHEMBL4562729 0.94 PAOX (0.58) TDP1ALOX15CA12CA2CA4
SCHEMBL4561516 0.94 PAOX (0.58) TDP1ALOX15CA12CA2CA4
SCHEMBL322792 0.91 ALOX15 (0.54) TDP1ALOX15CA12CA2CA4
SCHEMBL4562850 0.91 PAOX (0.53) TDP1ALOX15CA12CA2CA4
SCHEMBL322920 0.89 PAOX (0.53) TDP1ALOX15CA12CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016125163-A1 LIPID ASSEMBLIES AND USES THEREOF AND SOME pH AND ELECTROSTATIC MODULATING LIPIDS TO BE USED IN SAID ASSEMBLIES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2016-08-11 WO claimed
WO-2013122751-A1 COMPOSITIONS AND METHODS FOR CONTRACEPTION FIRESTONE, RAYMOND, A. (US) 2013-08-22 WO claimed
EP-1937235-A2 METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS Pathologica, LLC. (US) 2008-07-02 EP claimed
US-20070078187-A1 METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS PATHOLOGICA, LLC. (US) 2007-04-05 US claimed
WO-2007035957-A2 METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS PATHOLOGICA, LLC. (US) 2007-03-29 WO claimed
US-7087648-B1 Methods for modulating macrophage proliferation using polyamine analogs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-08-08 US claimed
US-20050159493-A1 Methods for modulating macrophage proliferation using polyamine analogs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2005-07-21 US claimed
US-20050113455-A1 Method and composition for amelioration of pain UNIVERSITY OF FLORIDA 2005-05-26 US claimed
WO-2005041988-A1 METHOD AND COMPOSITION FOR PAIN AMELIORATION UNIVERSITY OF FLORIDA (US) 2005-05-12 WO claimed
JP-2001520990-A 2001-11-06 JP claimed
EP-1027040-A2 METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS The Regents of the University of California (US) 2000-08-16 EP claimed
WO-1999021542-A2 METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-05-06 WO claimed
EP-0536853-B1 Process for the preparation of N1,N4-diethylspermine UNIV FLORIDA (US) 1996-03-27 EP claimed
US-5498522-A ANTITUMOR AGENTS OR ANTICARCINOGENIC AGENTS HEALTH RESEARCH, INC. (US) 1996-03-12 US claimed
EP-0568338-A2 Methods for the use of spermidine/spermine N'-acetyltransferase as a progonostic indicator and/or a tumor response marker HEALTH RESEARCH, INC. (US) 1993-11-03 EP claimed
EP-0270349-B1 USE OF AN ANTI-NEOPLASTIC SPERMINE DERIVATIVE IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION UNIV FLORIDA (US) 1993-08-04 EP claimed
EP-0536853-A2 Process for the preparation of N1,N4-diethylspermine THE UNIVERSITY OF FLORIDA (US) 1993-04-14 EP claimed
EP-0270349-A2 Use of an anti-neoplastic spermine derivative in the preparation of a pharmaceutical composition THE UNIVERSITY OF FLORIDA (US) 1988-06-08 EP claimed
JP-6062896-A None JP disclosed
EP-0270349-A2 Use of an anti-neoplastic spermine derivative in the preparation of a pharmaceutical composition THE UNIVERSITY OF FLORIDA (US) 1988-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078187-A1 METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS GLS, SHMT2, ARG2 TDP1 1614/4885ALOX15 2716/4885CA12 3056/4885
US-20050113455-A1 Method and composition for amelioration of pain SIGMAR1, ADORA2B, OPRL1 TDP1 3234/4885ALOX15 2427/4885CA12 1722/4885
US-20050159493-A1 Methods for modulating macrophage proliferation using polyamine analogs ARG1, MKI67, CSF1R TDP1 1008/4885ALOX15 814/4885CA12 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.